
Innate Pharma SA
PAR:IPH

Intrinsic Value
The intrinsic value of one
IPH
stock under the Base Case scenario is
3.558
EUR.
Compared to the current market price of 1.968 EUR,
Innate Pharma SA
is
Undervalued by 45%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Innate Pharma SA
Fundamental Analysis

Revenue & Expenses Breakdown
Innate Pharma SA
Balance Sheet Decomposition
Innate Pharma SA
Current Assets | 85.7m |
Cash & Short-Term Investments | 80.8m |
Receivables | 5m |
Non-Current Assets | 25.3m |
Long-Term Investments | 10.3m |
PP&E | 5.1m |
Other Non-Current Assets | 9.9m |
Free Cash Flow Analysis
Innate Pharma SA
EUR | |
Free Cash Flow | EUR |
Earnings Waterfall
Innate Pharma SA
Revenue
|
12.6m
EUR
|
Operating Expenses
|
-64.2m
EUR
|
Operating Income
|
-51.6m
EUR
|
Other Expenses
|
2.1m
EUR
|
Net Income
|
-49.5m
EUR
|
IPH Profitability Score
Profitability Due Diligence
Innate Pharma SA's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

Score
Innate Pharma SA's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
IPH Solvency Score
Solvency Due Diligence
Innate Pharma SA's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Score
Innate Pharma SA's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IPH Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for
IPH
is 5.269 EUR
with a low forecast of 2.454 EUR and a high forecast of 8.82 EUR.
Dividends
Current shareholder yield for IPH is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
IPH
stock under the Base Case scenario is
3.558
EUR.
Compared to the current market price of 1.968 EUR,
Innate Pharma SA
is
Undervalued by 45%.